6-ketoprostaglandin-f1-alpha and Myeloproliferative-Disorders

We have evaluated the arachidonic acid (AA) metabolism in patients with myeloproliferative disorders (MPD). In essential thrombocythemia (ET), the generation of thromboxane B2 was found significantly reduced and inversely correlated with platelet count. Polycythemia vera (PV) patients showed an increased formation of this metabolite of AA. Prostaglandin E2 and 6-keto-PGF1 alpha generation were markedly reduced in patients with chronic myelogenous leukemia. Our study confirms that the arachidonate metabolism is frequently deranged in patients with MPD. The opposite changes in thromboxane formation in ET and PV could be one of the factors responsible for the different incidences of thrombotic and hemorrhagic complications in these diseases.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Arachidonic Acid; Arachidonic Acids; Bleeding Time; Dinoprostone; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Myeloproliferative Disorders; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential; Thromboxane B2

Platelet functions were studied in 64 patients with various myeloproliferative diseases. The characteristic alterations were prolonged bleeding time, decreased platelet aggregation (but normal results induced by ristomycin), elevated level of BTG, high production of MDA, increased level of TXB2 with almost normal level of 6-keto-PGF1. However, considering the bleeding time and the amount of BTG in relation to the whole blood platelet count, no differences could be detected.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; beta-Thromboglobulin; Blood Platelets; Female; Humans; Male; Malondialdehyde; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation; Platelet Count; Platelet Function Tests; Thromboxane B2

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Biological Assay; Biopsy; Epoprostenol; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloproliferative Disorders; Polycythemia Vera; Thrombocytosis; Veins